{
  "label": "q_cs03_q17_temporal",
  "artifact_type": "question",
  "artifact_id": "sha256:7c3f933970429c39f8936b2e42fed220a27e8e512ecb29db1038bc43d02095b7",
  "input_ids": [
    "sha256:b4ba5337b06c8de68ac3315db1a4f6980c5bd48efd529c3914f30297d6afd329",
    "sha256:cab0ed69f1fa476255e68bf8c3e4cc9b8de1271b593421292819215fb07dd0fd",
    "sha256:bd89cf127fe8ce28af2609c702fd06647b82347034cf0bfb835b2f19a4d19bd1",
    "sha256:526bf0877b15ba594954d8544c6493f2535bc8acb2239824a0eeeb941d801b2d"
  ],
  "prompt_id": null,
  "model_config": null,
  "created_at": "2026-02-17T12:01:44.859982",
  "content": "{\n  \"question_id\": \"cs03_q17_temporal\",\n  \"scope_id\": \"clinical_signal_03\",\n  \"checkpoint_after\": 20,\n  \"question_type\": \"temporal\",\n  \"prompt\": \"How rapidly are ALT values escalating in the affected subgroup?\",\n  \"ground_truth\": {\n    \"canonical_answer\": \"ALT values in the statin subgroup have progressed from baseline normal (15-35 U/L) through subtle elevation (45-65 U/L) to clinically significant levels (80-120 U/L, 2-3x ULN) over the course of the signal and escalation phases. The rate of increase has accelerated.\",\n    \"required_evidence_refs\": [\n      \"clinical_signal_03_ep_010\",\n      \"clinical_signal_03_ep_017\",\n      \"clinical_signal_03_ep_019\"\n    ],\n    \"key_facts\": [\n      \"ALT elevations are concentrated in subjects receiving concurrent statin therapy, with higher-dose statin subgroups showing proportionally greater enzyme increases\",\n      \"the hepatic enzyme pattern is consistent with a drug-drug interaction mediated through shared hepatic metabolism pathways, not direct hepatotoxicity\",\n      \"ALT elevations appeared progressively over multiple weeks of statin co-administration with onset timing correlating with cumulative exposure duration rather than a single acute event\",\n      \"the adverse signal is hepatic (ALT/AST elevation), not renal \\u2014 kidney function markers remain stable while liver enzymes diverge\",\n      \"musculoskeletal safety endpoints track within expected ranges, confirming the safety signal is organ-specific to the liver\",\n      \"multi-site signal distribution rules out site-specific confounders as causal explanation\",\n      \"Site 07 lab equipment issue is not the cause of ALT elevations\",\n      \"the ALT elevation pattern correlates with statin co-administration timing, not with immune activation or antibody response patterns\"\n    ]\n  }\n}",
  "metadata": {
    "question_id": "cs03_q17_temporal",
    "question_type": "temporal",
    "checkpoint_after": 20,
    "scope_id": "clinical_signal_03",
    "layer_name": "questions",
    "layer_level": 3,
    "build_fingerprint": {
      "scheme": "synix:build:v1",
      "digest": "06b9ddd953618220897f3035b6367ebe3823ae0a8401844853829ba0e5a33727",
      "components": {
        "transform": "a7d463dc476b419c96a5f454f481b455ca81a8d8ee3904631b7729963317406f",
        "inputs": "cdb2845e0af9f229"
      }
    },
    "transform_fingerprint": {
      "scheme": "synix:transform:v2",
      "digest": "a7d463dc476b419c96a5f454f481b455ca81a8d8ee3904631b7729963317406f",
      "components": {
        "transform_id": "3176c030aaa3a69e",
        "source": "929fe273ac2dab06",
        "model": "1e2ccf75e96d7ee7"
      }
    }
  }
}